Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cervical cancer: combined modality therapy.

P W Grigsby1

  • 1Mallinckrodt Institute of Radiology, Washington University Medical Center, St Louis, Missouri 63110, USA.

Cancer Journal (Sudbury, Mass.)
|August 16, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-Term Outcomes of Cervical Cancer Patients Treated With Definitive Chemoradiation Following a Complete Metabolic Response.

Clinical oncology (Royal College of Radiologists (Great Britain))·2021
Same author

FDG-PET/CT: new horizons in anal cancer.

Gastroenterologie clinique et biologique·2009
Same author

Nuclear imaging and cervical cancer.

Minerva ginecologica·2009
Same author

MicroRT-small animal conformal irradiator.

Medical physics·2008
Same author

Gene expression patterns in advanced human cervical cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2006
Same author

Postoperative vaginal brachytherapy alone is the treatment of choice for grade 1-2, stage IC endometrial cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2005

Recent studies show chemotherapy improves survival in advanced cervical cancer. Adding prophylactic para-aortic irradiation also benefits patients with stages IB-IIB cervical cancer.

Area of Science:

  • Gynecologic Oncology
  • Radiation Oncology
  • Medical Oncology

Background:

  • Advanced cervical cancer management has evolved significantly over the last decade.
  • Prospective, randomized studies have investigated various treatment modalities including surgery, irradiation, and chemotherapy.

Purpose of the Study:

  • To review and summarize findings from recent prospective, randomized studies on the management of advanced cervical cancer.
  • To evaluate the impact of different treatment strategies on survival and recurrence rates.

Main Methods:

  • Review of prospective, randomized studies from the past 10 years.
  • Analysis of treatment outcomes for various stages of cervical cancer, considering high-risk factors.
  • Specific studies examined included comparisons of pelvic irradiation with pelvic plus para-aortic irradiation, and the addition of chemotherapy (cisplatin, 5-FU) and hydroxyurea.

Related Experiment Videos

Main Results:

  • Prophylactic para-aortic irradiation showed an 11% survival advantage in stages IB-IIB cervical cancer.
  • Chemotherapy (cisplatin and 5-FU) significantly improved overall and disease-free survival in patients with stages IB-IVA cervical cancer.
  • Concurrent chemoradiation with weekly cisplatin is now standard therapy for stages IIB-III, and optimal for stage IB cervical cancer.
  • Postoperative pelvic irradiation improved recurrence-free interval by 10% in stage IB patients.
  • Concurrent chemotherapy with postoperative pelvic irradiation significantly improved overall and progression-free survival in high-risk patients (positive lymph nodes/parametrial involvement).

Conclusions:

  • Chemotherapy, particularly cisplatin-based regimens, is crucial for improving survival in advanced cervical cancer.
  • Prophylactic para-aortic irradiation offers survival benefits for specific stages.
  • Concurrent chemoradiation is the standard of care for many advanced cervical cancer patients.
  • Risk stratification based on factors like tumor size, invasion depth, and lymph node status is essential for tailoring treatment.